What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
TACE Plus Lenvatinib and a PD-1 Antibody Appears Safe, Effective in Advanced uHCC
January 21st 2022The combination of transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade demonstrated tolerable safety and efficacy in patients with unresectable advanced hepatocellular carcinoma.
Read More
Investigating TACE With Nivolumab in Hepatocellular Carcinoma
October 12th 2021Arndt Vogel, MD, discusses the trial design of IMMUTACE, which is evaluating the efficacy of transarterial chemoembolization in combination with nivolumab for the treatment of intermediate-stage hepatocellular carcinoma.
Watch
Vogel Discusses Real-World Survival Data of Immunotherapy in HCC
October 10th 2021Arndt Vogel, MD, the managing senior consultant and professor in the department of Gastroenterology, Hepatology, and Endocrinology, at the Hannover Medical School, discusses the real-world data of immunotherapy combinations in hepatocellular carcinoma.
Watch